Jefferies Financial Group upgraded shares of UCB (OTCMKTS:UCBJF) from an underperform rating to a hold rating in a research report sent to investors on Tuesday morning, The Fly reports. Jefferies Financial Group also issued estimates for UCB’s FY2018 earnings at $5.53 EPS, FY2019 earnings at $5.79 EPS, FY2020 earnings at $6.47 EPS, FY2021 earnings at $6.99 EPS and FY2022 earnings at $6.88 EPS.

UCBJF stock opened at $94.30 on Tuesday. UCB has a one year low of $69.80 and a one year high of $90.45.

UCB Company Profile

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.

Featured Article: How to Invest in an Index Fund

The Fly

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.